Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and Bioavailability of PBT2 in Healthy Males
NCT02249728Phase 1Completed
- Sponsor
- Alterity Therapeutics
- Start
- Jun 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PBT2 in Alzheimer's disease (AD) and Huntington's disease (HD) (2 arms), sponsored by Alterity Therapeutics. Primary endpoints: Absolute Bioavailability of PBT2 (F%) and Mass Balance at 168 hours. Started Jun 2014; status: completed.
02
Drugs
PBT2
03
Conditions
Alzheimer's disease (AD)Huntington's disease (HD)
Beyond the preview
Go deeper on NCT02249728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249728.